PATIENT PERSPECTIVES OF PRE-FILLED SYRINGE ADMINISTRATION OF SUBCUTANEOUS IMMUNOGLOBULIN: A QUALITATIVE STUDY IN THE US
Author(s)
Batyrkhan Kuatov, MSc1, Gemma Al-Jassar, MSc2, Katja Rudell, BSc, MSc, PhD2, Tommi Tervonen, PhD3, Anita D. Burrell, BA, MA, MBA4, Shicheng Weng, M.S.5, Julia Braverman, PhD5;
1CSL Behring, Bern, Switzerland, 2Kielo Research, York, United Kingdom, 3Kielo Research, Zug, Switzerland, 4Anita Burrell Consulting LLC, Flemington, NJ, USA, 5CSL Behring, Waltham, MA, USA
1CSL Behring, Bern, Switzerland, 2Kielo Research, York, United Kingdom, 3Kielo Research, Zug, Switzerland, 4Anita Burrell Consulting LLC, Flemington, NJ, USA, 5CSL Behring, Waltham, MA, USA
OBJECTIVES: Patients with primary immunodeficiency (PID) can receive subcutaneous immunoglobulin (SCIG) therapy using vials or pre-filled syringes (PFS). This research explored patient experiences with both administration forms related to adherence, satisfaction, convenience, and impacts to quality of life.
METHODS: A cross-sectional, qualitative interview study was conducted with 24 patients with PID from the United States who are currently administering immunoglobulin using PFS but who have prior experience in using vials.
RESULTS: Of the 24 patients, 83% were female, the mean age was 51 years (range 23-79) and the mean time since diagnosis was 12 years (range 3-47). Most patients had extensive PFS administration experience (83% >24 months). The vast majority of patients (83%) reported being more satisfied with PFS than vials, finding them more convenient (75%) compared with their past experience with vials. Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to PFS, mainly related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.
CONCLUSIONS: Participants experienced in both SCIG administration forms were more satisfied, reported improved convenience, and were more adherent with PFS compared with vials. The benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their behavior.
METHODS: A cross-sectional, qualitative interview study was conducted with 24 patients with PID from the United States who are currently administering immunoglobulin using PFS but who have prior experience in using vials.
RESULTS: Of the 24 patients, 83% were female, the mean age was 51 years (range 23-79) and the mean time since diagnosis was 12 years (range 3-47). Most patients had extensive PFS administration experience (83% >24 months). The vast majority of patients (83%) reported being more satisfied with PFS than vials, finding them more convenient (75%) compared with their past experience with vials. Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to PFS, mainly related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.
CONCLUSIONS: Participants experienced in both SCIG administration forms were more satisfied, reported improved convenience, and were more adherent with PFS compared with vials. The benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their behavior.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR23
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
SDC: Rare & Orphan Diseases